What are the indications, dosing schedule, contraindications, and monitoring recommendations for Sativex (oromucosal spray containing Δ‑9‑tetrahydrocannabinol and cannabidiol) in adults with multiple‑sclerosis‑related spasticity?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Sativex for Multiple Sclerosis-Related Spasticity

Sativex (nabiximols) oromucosal spray containing THC:CBD is indicated as add-on therapy for adults with moderate-to-severe MS-related spasticity who have failed to respond adequately to conventional oral anti-spasticity medications (baclofen, tizanidine, diazepam, or dantrolene), and only after demonstrating clinically significant improvement during an initial 4-week trial period. 1, 2

Indications

Sativex is specifically approved for:

  • MS-related moderate-to-severe spasticity that remains inadequately controlled despite trials of first-line oral agents 2, 3
  • Patients must demonstrate ≥20% reduction in spasticity Numeric Rating Scale (NRS) score during the initial 4-week trial to continue treatment 3, 4

The evidence shows 70.5% of patients achieve this initial response threshold, with 28.2% reaching the more robust ≥30% improvement (clinically relevant response) 3. Do not continue Sativex beyond 4 weeks if the patient fails to achieve at least 20% NRS improvement - this represents treatment failure and exposes patients to unnecessary adverse effects 3.

Dosing Schedule

Initial Titration (First 2 Weeks)

  • Start with 1 spray daily (2.7 mg THC + 2.5 mg CBD per spray)
  • Self-titrate by adding 1 spray per day every 1-2 days
  • Divide doses throughout the day (morning, afternoon, evening)
  • Titrate to symptom relief or maximum tolerated dose 2, 5

Maintenance Dosing

  • Average effective dose: 5-7 sprays per day (range 4-8 sprays) 3, 5, 4
  • Maximum recommended: 12 sprays per day (32.4 mg THC + 30 mg CBD) 2, 6
  • Administer sprays under the tongue or inside the cheek, alternating application sites 2

Critical dosing caveat: Most adverse effects occur during the titration phase. If dizziness, fatigue, or cognitive effects develop, slow the titration rate or temporarily reduce dose by 1-2 sprays until tolerance develops 2, 5.

Contraindications

Absolute contraindications:

  • History of hypersensitivity to cannabinoids
  • Personal or family history of psychosis or schizophrenia 2
  • Severe cardiovascular disease
  • Pregnancy and breastfeeding 1

Relative contraindications requiring careful consideration:

  • History of substance use disorder (though abuse potential is low) 2, 5
  • Significant psychiatric illness (depression, anxiety disorders) - may exacerbate symptoms 1
  • Elderly patients with cognitive impairment
  • Concurrent use of CNS depressants (additive sedation risk)

Monitoring Recommendations

Initial 4-Week Trial Period

  • Week 1: Assess tolerability during titration; monitor for dizziness, sedation, cognitive effects
  • Week 4: Measure spasticity NRS score - discontinue if <20% improvement from baseline 3, 4
  • Document baseline and follow-up scores for spasticity-associated symptoms: pain, sleep quality, bladder function, mobility 6, 7

Ongoing Monitoring (for responders)

  • Month 3 and 6: Reassess spasticity NRS and functional outcomes 3
  • Every 6-12 months: Evaluate continued efficacy - sustained benefit without dose escalation indicates absence of tolerance 5
  • Monitor for psychiatric symptoms: mood changes, anxiety, hallucinations (rare but serious) 5
  • Assess for falls risk, particularly in patients with baseline mobility impairment 7

Safety Monitoring

  • No routine laboratory monitoring required - unlike dantrolene (hepatotoxicity) or tizanidine (liver function) 8
  • Screen for cannabis use disorder symptoms if dose escalation occurs beyond 8 sprays/day 1
  • Counsel on impaired driving - reaction time and coordination may be affected 1

Efficacy Beyond Spasticity

The evidence demonstrates Sativex improves multiple spasticity-associated symptoms beyond the primary spasticity measure 6, 7:

  • Pain reduction in 92% of patients (11/12 in case series) 7
  • Sleep quality improvement - complete resolution in 25%, improvement in 67% 7
  • Bladder dysfunction improvement in 86% (6/7 patients) 7
  • Spasm frequency reduction or complete resolution 7

These improvements often occur even when spasticity reduction is modest, suggesting direct effects on these symptoms rather than solely secondary to spasticity improvement 6.

Common Pitfalls to Avoid

  1. Continuing treatment in non-responders: The 4-week trial is mandatory - 26.2% discontinue due to lack of efficacy, and prolonging ineffective treatment wastes resources and exposes patients to adverse effects 3

  2. Inadequate titration time: Rushing titration increases adverse effects (dizziness in 24.7%, fatigue in 12.3%) 5. Allow 1-2 weeks for full titration.

  3. Premature discontinuation for mild adverse effects: Most CNS effects are mild-moderate and resolve within days to weeks as tolerance develops 2, 5. Only 14% discontinue due to adverse events in long-term studies 5.

  4. Using as first-line therapy: Sativex is explicitly an add-on agent after conventional medications fail 2, 3. The 2024 AAPM&R guidelines note cannabinoids have moderate-quality evidence but recommend trying baclofen, tizanidine, or other agents first 8.

  5. Ignoring psychiatric screening: While serious psychiatric events are uncommon (3.4%), one patient in long-term studies experienced two psychiatric events requiring discontinuation 5. Screen carefully before initiating.

Evidence Quality and Limitations

The evidence base is moderate quality with important caveats 8, 9:

  • Substantial heterogeneity exists across studies (I² = 91-100%) 10
  • Most high-quality data comes from MS populations - generalizability to other spasticity causes is limited 8
  • The 2024 AAPM&R consensus rates cannabinoids as having "moderate-quality evidence" and notes "more research is needed" 8
  • Real-world observational studies (>1600 patients) confirm RCT findings, with 70.5% achieving initial response 3, 4

The most recent systematic review and meta-analysis (2026) confirms modest but clinically meaningful improvements in patient-reported spasticity (MD -0.82,95% CI -1.24 to -0.40), with low certainty of evidence requiring cautious use as adjunctive therapy 9.

References

Research

Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity.

Journal of neurology, neurosurgery, and psychiatry, 2016

Guideline

aapm&r consensus guidance on spasticity assessment and management.

PM&R (The Journal of Injury Function & Rehabilitation), 2024

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.